34 results about "Scutellarin" patented technology

The invention belongs to the field of preparation analysis, and discloses a method for establishing an HPLC (High Performance Liquid Chromatography) fingerprint spectrum of detoxification and hematogenesis granules. According to the invention, a method of combining the HPLC fingerprint spectrum and the chemical mode of the detoxification and hematogenesis granules is established, the contents of the deacetylasperuloside, the rosmarinic acid, the scutellarin, the luteolin, the apigenin and the kaempferol in the detoxification and hematogenesis granules are detected at the same time, and a comprehensive quality evaluation model of the detoxification and hematogenesis granules with different batch numbers is established, so that the analysis result is comprehensive and objective; the method is simple, convenient, reliable, good in repeatability, accurate, stable and high in sensitivity, the multi-component content determination method provides scientific support for quality supervision of the Zhuang medicine preparation detoxification and hematopoiesis granules, and the method can be used for comprehensive quality evaluation and control of the detoxification and hematopoiesis granules. Therefore, the production stability of product quality and the safety and effectiveness of clinical medication are ensured.

The invention belongs to the field of biological medicine, and relates to a rosmarinic acid and scutellarin compatible composition and application thereof. The invention specifically discloses a rosmarinic acid and scutellarin composition as shown in formulas (I) and (II), and the rosmarinic acid and scutellarin composition is applied to treatment and / or prevention of acute lung injury. The screened rosmarinic acid and scutellarin composition is simple in preparation method, has a potential synergistic treatment effect on acute lung injury, has a remarkable treatment effect on lung functions, alveolar lavage fluid inflammatory factors and serum inflammatory indexes of LPS-induced mouse acute lung injury, and has a good application prospect. And compared with the toxic and side effects of dexamethasone on reducing body weight, the dexamethasone shows good safety, and meanwhile, the dexamethasone shows a remarkable inhibition effect on secretion of primary peritoneal macrophages NO, TNF-alpha and IL-6 in vitro. In conclusion, the rosmarinic acid and scutellarin composition can be in the form of a single composition or a medicinal composition, and has potential application value in treatment of acute lung injury and immune-related diseases. # imgabs0 #

The invention discloses application of a combination of scutellarin and salidroside in treatment of solar dermatitis, finds that the combination of scutellarin and salidroside has a synergistic effect on treatment of solar dermatitis for the first time, and provides a brand new and effective drug combination strategy for treatment of solar dermatitis. A new thought is provided for research and development of anti-solar dermatitis drugs, and the application value and the industrial conversion prospect are good.

The invention provides a composition with whitening and anti-aging effects as well as a preparation method and application thereof, and belongs to the technical field of medicines or cosmetics. The composition is prepared from the following components: cucurbitacine F, sutherlandin-5-trans-p-coumarate, quercetin, rutin, wogonin, trilobatin, quercetin-3-O-beta-D-xyloside, scutellarin, hyperoside, cinchona element Ib, kaempferol-3-furan arabinoside, arbutin and astragalus smicus glycoside. The preparation method comprises the following steps: preparing the cucurbitacine F, the sutherlandin-5-trans-p-coumarate, the quercetin, the rutin, the wogonin, the trilobatin, the quercetin-3-O-beta-D-xyloside and the scutellarin; the composition has the remarkable effects of whitening skin, fading spots, delaying senescence and the like, is suitable for various skin types such as dry skin types, oily skin types, mixed skin types and sensitive skin types, and has high biological application value in the fields of cosmetics and medicines.

The invention discloses a construction method and application of a scutellaria baicalensis stem and leaf fingerprint spectrum, and belongs to the technical field of medicine quality control. The method comprises the following steps: preparing standard substance solutions of scutellarin, baicalin, taxifolin and isoschaftoside; preparing a scutellaria baicalensis stem and leaf sample solution; detection is carried out under specific conditions through high performance liquid chromatography, a standard fingerprint spectrum of the stems and leaves of scutellaria baicalensis is made by taking a standard chromatographic peak as a reference, and the relative standard deviation of the relative retention time does not exceed + / -20%. The method disclosed by the invention is high in precision, good in stability and excellent in repeatability, effective separation of four flavonoid components can be realized within 35 minutes, and the quality characteristics of stems and leaves of scutellaria baicalensis are comprehensively reflected. The invention further provides application of the fingerprint spectrum in quality analysis of the scutellaria baicalensis stem and leaf medicinal material and the extract thereof, and reliable technical support is provided for resource development and quality control of the scutellaria baicalensis stem and leaf.

The present invention relates to a method for preparing withangulatin A and its use in preparing anti-tumor drugs, which belongs to the field of medical technology. Specifically, it relates to a method for preparing withangulatin A and its use in preparing anti-tumor drugs. The present invention provides a rapid preparation method for withangulatin A, which has a simple preparation process and a high extraction rate, thereby ensuring the large-scale enrichment of withangulatin A. The preparation process of the present invention does not use toxic and harmful solvents, and the process is environmentally friendly. The product yield is high, the content is high, the process is simple and safe, the equipment requirements are low, and the production cost is low. In addition, the present invention also discovered that withangulatin A has anti-tumor effects against various types of cancer, especially that withangulatin A enhances the sensitivity of PI3K inhibitors to triple-negative breast cancer cells, and the two have a synergistic anti-tumor effect.

The invention relates to a KASP molecular marker associated with scutellarin of erigeron breviscapus and application of the KASP molecular marker, and belongs to the technical field of genetic engineering. The primers of the KASP molecular marker associated with the scutellarin of the erigeron breviscapus comprise a forward primer 1, a forward primer 2 and a common reverse primer; the nucleotide sequence of the forward primer 1 is as shown in SEQ ID NO. 1; the nucleotide sequence of the forward primer 2 is as shown in SEQ ID NO. 2; the nucleotide sequence of the common reverse primer is as shown in SEQ ID NO.3. By utilizing the KASP technology, the SNP site and the corresponding primer combination provided by the invention not only improve the plant variety selection efficiency, but also are beneficial to shortening the breeding cycle and accelerating the cultivation of high-quality plant varieties. The markers have good genetic stability and high resolution, are suitable for high-throughput detection, and have significant application value in the field of plant breeding.

The invention belongs to the field of medicines, and relates to a scutellarin aglycone derivative as well as a preparation method and application thereof. The scutellarin aglycone derivative has a structure as shown in a formula I. The preparation method comprises the following steps: reacting scutellarin (a compound II) with methanol to obtain a compound III, then reacting with bornyl chloroacetate (a compound IV) to obtain a compound V, and finally carrying out an alkaline hydrolysis reaction to obtain the compound I, the scutellarin aglycone derivative has the effect of preventing or treating cardiovascular and cerebrovascular related diseases, can improve the activity of superoxide dismutase (SOD), inhibit the production of lactic dehydrogenase (LDH) and reduce the malondialdehyde (MDA) level superior to that of scutellarin, has the inhibiting effect on inflammatory factors TNF-alpha, IL-6 and IL-1beta in cell supernatant superior to that of scutellarin, and can be used for preparing a medicine for treating cardiovascular and cerebrovascular related diseases, such as cardiovascular and cerebrovascular related diseases, cardiovascular and cerebrovascular related diseases, cardiovascular and cerebrovascular related diseases, cardiovascular and cerebrovascular related diseases, cardiovascular and cerebrovascular related diseases, cardiovascular and cerebrovascular related diseases and cardiovascular and cerebrovascular related diseases. The invention has the potential of preparing or preventing cardiovascular and cerebrovascular related diseases.

The invention belongs to the technical field of medicine detection, and particularly relates to a method for detecting erigeron breviscapus formula granules, the erigeron breviscapus formula granules are prepared by decocting, concentrating, drying and granulating erigeron breviscapus decoction pieces, and the detection method comprises the items of character determination, identification, inspection, extract determination, characteristic spectrum determination and content determination. According to the identification method, thin-layer chromatography is adopted for identification; the characteristic chromatogram is characterized in that 11 characteristic peaks are marked by adopting a high performance liquid chromatography and taking a scutellarin reference substance peak as an S peak; and the content determination is to detect the content of scutellarin. According to the detection method established by the invention, the detection requirements on erigeron breviscapus medicinal materials, decoction pieces, standard decoction and formula granules are improved, establishment of a perfect quality control system for each product of erigeron breviscapus is facilitated, and the quality and clinical curative effect of the erigeron breviscapus formula granules are guaranteed.

The invention provides a construction method and application of a fingerprint spectrum of Hexishi chrysanthemum. The construction method comprises the following steps: a) preparation of reference substance solutions: taking aesculetin, scutellarin, apigenin and luteolin as reference substances, respectively adding solutions for dissolving to obtain the reference substance solutions, and the reference substance solutions comprise an aesculetin solution, a scutellarin solution, an apigenin solution and a luteolin solution; b) preparation of a test solution: mixing the powder of the Hexishi chrysanthemum with a methanol solution, carrying out heating reflux treatment, cooling, and filtering to obtain the test solution; and c) placing the test solution and the plurality of reference substance solutions in a high performance liquid chromatograph, and measuring to obtain a high performance liquid chromatogram of the test solution and high performance liquid chromatograms of the reference substance solutions. The method can solve the problem of lack of a method for controlling the quality of the Hexishi chrysanthemum in the prior art, and is suitable for the field of traditional Chinese medicine analysis.

The invention discloses a method for detecting a Wantongkang in-blood core bioactive component group and verification, serum, urine and excrement are collected as an experimental group after a preset time, and serum, urine and excrement of animals not given with Wantongkang are used as a control group; and detecting the experimental group and the control group by adopting liquid chromatography-mass spectrometry. The invention systematically analyzes the original components and metabolites of Wantongkang in blood plasma, urine and excrement of rats. 38 primordial components are detected in plasma, 48 urine and 89 excrement. The terpenoids may form a core pharmacodynamic material basis of WTYK for treating pharyngitis. A metabolic conversion path of picria fel-terrae glycoside IA, rosmarinic acid, isofraxidin, caffeic acid and apigenin-7-O-glucuronide is constructed through metabolic conversion analysis, and active metabolites of picria fel-terrae glycoside IA, rosmarinic acid, isofraxidin, caffeic acid and The network pharmacological research based on the in-blood component reveals that the WTYK plays a therapeutic role in treating the pharyngitis mainly by regulating key signal channels such as PI3K-Akt, MAPK, TNF, JAK-STAT and NF-kB, wherein the NF-kB signal channel is closely related to the occurrence and development of the pharyngitis.

The present invention relates to a salt formed by berberine and scutellarin, and its preparation method and application. The structure of the berberine scutellarin salt is:

This invention provides a method for extracting active ingredients from *Erigeron breviscapus*, belonging to the field of pharmaceutical technology. Based on the differences in the physicochemical properties of the compounds, this invention first achieves preliminary separation of caffeic acid esters and scutellarin, followed by further purification and separation based on the properties of the two types of substances. Specifically, this invention uses ethanol-water solutions of different concentrations to extract caffeic acid esters stepwise, and uses macroporous and microporous resins for preliminary separation of the caffeic acid esters. Scutellarin is then preliminarily separated through acid-base treatment. Finally, high-purity scutellarin, 3,5-dicaffeoylquinic acid, 3,4-dicaffeoylquinic acid, 4,5-dicaffeoylquinic acid, and scutellarin are obtained through reversed-phase industrial chromatography. This invention achieves the extraction and separation of multiple active ingredients from *Erigeron breviscapus*, and all solvents used in the extraction and separation process are recyclable, resulting in low cost.

The invention belongs to the technical field of medicines, and particularly relates to novel application of scutellarein in preparation of medicines for treating depression, the scutellarein can effectively relieve depression symptoms of mice and drosophila melanogaster induced by a chronic unpredictable stress method, reverse decline of monoamine neurotransmitters and gamma-aminobutyric acid receptors and relieve neuroinflammation. The evidences show that scutellarein can improve depression symptoms.

The invention discloses a recombinant yarrowia lipolytica strain Ylscu-03 for producing scutellarin as well as a construction method and application of the recombinant yarrowia lipolytica strain Ylscu-03, and belongs to the technical field of genetic engineering and metabolic engineering. The recombinant yarrowia lipolytica strain Ylscu-03 is constructed by the following steps: introducing SlA-Tsynth7, SUMO-FNS I-Tsynth27, VPRHX, Pleu-Pxo-Ptef, F7GAT-Tsynth2, UDPGDH-Tsynth8 and TAL-Tsynth7 into a recombinant yarrowia lipolytica engineering strain Ylscu2-00, replacing an original promoter of a yeast endogenous pre-benzoic acid dehydratase gene PHA2 with a core promoter pPHA2-50, and introducing BbXFPK-Tsynth22 and BsPTA-Tsynth7, so that the recombinant yarrowia lipolytica strain Ylscu-03 is obtained. And the yield of scutellarin produced by fermenting Ylscu-03 for 84 hours can reach 6407.63 mg / L.

The present invention relates to a preparation method of an Erigeron breviscapus extract, its product and application. The preparation method of the Erigeron breviscapus extract comprises the following steps: mixing an Erigeron breviscapus raw material with an extraction solvent and then carrying out water bath heating extraction, centrifuging and filtering the extraction solution to obtain a filtrate, thus obtaining the extract; the extraction solvent is selected from a deep eutectic solvent or a mixed solvent of a deep eutectic solvent and water. This preparation method creatively uses a deep eutectic solvent or a mixed solvent of a deep eutectic solvent and water to extract the Erigeron breviscapus raw material. On the one hand, it can make the contents of scutellarin and total flavonoids in the obtained extract high, providing an effective strategy for the utilization of the Erigeron breviscapus raw material and the preparation of scutellarin; on the other hand, the obtained extract also has excellent inhibitory activities against hyaluronidase, elastase and collagenase, excellent promoting expression activities of aquaporin, filaggrin and involucrin, excellent anti-free radical activity and excellent anti-aging activity.

The invention relates to scutellarin-loaded brain tissue exosome nanoparticles and application thereof in preparation of a medicine for treating diseases by penetrating through a blood brain barrier, and belongs to the technical field of medicines. Brain tissue exosome nanoparticles loaded with scutellarin are added into mouse microglial cells, astrocytes and brain microvascular endothelial cells, so that the nanoparticles can regulate the polarization of the microglial cells caused by PRV infection, remarkably inhibit the expression of M1 type microglial cells CD86, promote the expression of M2 type microglial cells CD 206, inhibit the expression of the PRV infection, and inhibit the PRV infection. The anti-inflammatory effect is achieved; through in-vitro Transwell blood brain barrier and blood brain barrier penetration test of the exosome of a living brain tissue model, it is obtained that the brain tissue exosome can enhance the brain delivery efficiency of scutellarin. The scutellarin-loaded brain tissue exosome nanoparticles provided by the invention solve the problems of difficult scutellarin blood brain barrier penetration and low bioavailability, and have important practical significance in prevention and control of porcine pseudorabies.

To provide a novel composition that exhibits a promotion effect on production of nicotinamide adenine dinucleotide in vivo.SOLUTION: The present invention provides a composition for promoting production of nicotinamide adenine dinucleotide (NAD) in vivo, the composition containing scutellarin as an active ingredient.SELECTED DRAWING: None

The invention provides a traditional Chinese medicine composition with a hypoglycemic effect, the traditional Chinese medicine composition is prepared from traditional Chinese medicinal materials of cyclocarya paliurus and gynostemma pentaphyllum according to specific parts by weight, and the traditional Chinese medicine composition contains the following effective components: rutin, scutellarin, chlorogenic acid, kaempferol, quercetin-3-glucuronide, cryptochlorogenic acid, kaempferol-3-O-rutinoside and thesium chinense element I. The traditional Chinese medicine composition has the hypoglycemic effect. The invention further provides a preparation, a preparation method and application of the traditional Chinese medicine composition.

The present invention belongs to the field of immunology, and discloses a culture method for improving the killing activity of NK cells. It comprises the following steps: (1) isolating and obtaining peripheral blood mononuclear cells, (2) coating a culture bottle with a coating solution, and inducing and culturing in a culture medium containing rice oligopeptides, docosahexaenoic acid, IL-15 and IL-12; (3) amplifying and culturing in a culture medium containing DMEM culture medium, pyrazinecarboxamide, scutellarin, glutamine, IL-2 and IL-21 to obtain NK cells. In the present invention, rice oligopeptides and docosahexaenoic acid can act synergistically to promote the induced differentiation of NK cells, and can cooperate with pyrazinecarboxamide and scutellarin in the amplification culture medium to effectively improve the in vitro tumor killing activity of NK cells, which plays an important role in tumor immunotherapy.

The invention relates to a cell sugar and lipid metabolism regulation type drug-loaded linoleic acid lipid hybrid vesicle as well as a preparation method and application thereof, and the cell sugar and lipid metabolism regulation type drug-loaded linoleic acid lipid hybrid vesicle comprises a linoleic acid lipid hybrid vesicle, a sugar metabolism drug and a lipid metabolism drug, the glycometabolism drug and the lipid metabolism drug are loaded in the linoleic acid lipid hybrid vesicles; wherein the glycometabolism medicine is prepared from alkannin, tripterine, scutellarin or luteolin, and the lipid metabolism medicine is prepared from cinnamyl aldehyde, curcumin, myricetin, squalene or diclofenac sodium. The drug-loaded linoleic acid lipid hybrid vesicles prepared by the invention have uniform particle size and very stable structure and property, are naturally targeted to macrophages, can enhance the ability of host cells to remove intracellular bacteria, and have a remarkable effect on treatment of staphylococcus aureus and escherichia coli drug-resistant bacterial infection.

The invention discloses a traditional Chinese medicine composition for preventing and treating cerebral arterial thrombosis and a screening method thereof, and the effective components of the traditional Chinese medicine composition comprise the following substances in parts by weight: 30-50 parts of 3-caffeoylquinic acid, 20-40 parts of 4, 5-dicaffeoylquinic acid and 30-50 parts of scutellarin. The traditional Chinese medicine composition disclosed by the invention has an obvious improvement effect on cerebral arterial thrombosis, and can also protect damaged neurons, improve the activity of nerve cells and effectively relieve cerebral arterial thrombosis injury. Meanwhile, according to the screening method of the composition, a regression model with brain protection related indexes as dependent variables and the proportion of all the components as independent variables is established through mixed material design, the predictive ability of the model is evaluated, and after the predictive ability of the model reaches the standard, synchronous optimization of the multiple brain protection indexes is carried out; and solving the optimal ratio of each component and carrying out experimental verification. The traditional Chinese medicine composition screened by the method is stable in activity and exact in effect.

The invention discloses a method for increasing the contents of baicalin and scutellarin in a scutellaria baicalensis extract. The method comprises the following steps: (1) preparing a scutellaria baicalensis extracting solution; (2) loading a sample; (3) collecting an eluent; and (4) acid precipitation and purification: preparing the total eluate into a solution with a certain mass concentration, adding acid to adjust the pH value, storing at a proper temperature, standing in a refrigerator, filtering, separating and precipitating, washing the precipitate with water and ethanol until the pH value is neutral, volatilizing the ethanol until no alcohol smell exists, and drying in a drying oven until the weight is constant to obtain the scutellaria baicalensis extract. Wherein the active ingredients comprise scutellarin and baicalin. According to the method, macroporous adsorption resin and acid precipitation are sequentially used for purification, the content and the yield of scutellarin can be effectively increased while the content and the yield of scutellarin are guaranteed, and the method is stable and reliable and can provide thoughts for actual quality improvement and process development.

The invention belongs to the field of pharmaceutical preparations, particularly relates to a scutellarein preparation composition, and provides a scutellarein suspension, freeze-dried powder and gel as well as a preparation method and application of the scutellarein suspension, freeze-dried powder and gel. The suspension is prepared by an anti-solvent precipitation method, a solid preparation with small and uniform average particle size is prepared by adding lecithin, adopting a proper stabilizer and optimizing the concentration of the stabilizer, the medicine and lecithin and the composition and volume ratio of an organic phase, and the crystal form and the chemical structure of the obtained medicine are not obviously changed; the dissolution rate of the medicine and the stability of the preparation are improved. The suspension is further prepared into freeze-dried powder and gel, and in treatment of a skin itch model, compared with the gel directly prepared from the scutellarein, the gel prepared from the scutellarein freeze-dried powder obviously reduces the scratching frequency of mice, inhibits thickening of the epidermis of the neck and the back, and shows a better treatment effect.

The resin provided by the invention is of a white semitransparent spherical structure, the water content is 55%-70%, the particle size distribution is 0.425-1.00 mm, the specific surface area is 560-750 m < 2 > / g, the pore diameter is intensively distributed in a region of 10-30 nm, and the average pore diameter is 9.35-10.35 nm. The resin is of a white semitransparent spherical structure, the water content is 55%-70%, the particle size distribution is 0.425-1.00 mm, the specific surface area is 560-750 m < 2 > / g, the pore diameter is intensively distributed in a region of 10-30 nm, and the average pore diameter is 9.35-10.35 nm. The resin has the characteristics of high porosity, high specific surface area and uniform resin pore size distribution. In the same technological process for preparing scutellarin through extraction and chromatographic purification of erigeron breviscapus; the resin (the scutellarin adsorption rate is 90.12%, and the product content is 90.33%) is higher in purification efficiency and wider in application range compared with common industrial macroporous adsorption resin ADS-2 (the scutellarin adsorption rate is 19.16%, and the product content is 73.20%), HPD450 (the scutellarin adsorption rate is 21.34%, and the product content is 81.38%), AB-8 (the scutellarin adsorption rate is 15.01%, and the product content is 79.11%) and D101 (the scutellarin adsorption rate is 10.29%, and the product content is 78.68%).

The invention belongs to the field of biological medicine, and particularly relates to a scutellarin and luteolin compatible composition and application thereof. In particular discloses a scutellarin and luteolin compatible composition as shown in formulas (I) and (II), and the scutellarin and luteolin compatible composition is applied to treatment and / or prevention of chronic obstructive pulmonary diseases. The screened scutellarin and luteolin compatible composition is simple in preparation method, has a remarkable synergistic treatment effect on the chronic obstructive pulmonary disease, and has a remarkable treatment effect on airway inflammation and lung function impairment of a mouse with the chronic obstructive pulmonary disease induced by a cigarette smoke extract; meanwhile, the composition shows a remarkable inhibiting effect on a neutrophile granulocyte extracellular trap net released by LPS-induced primary mouse bone marrow neutrophile granulocyte, TNF-alpha and IL-6 in vitro, the two medicines have a synergistic effect, the improvement effect is obviously superior to that of a single medicine, and the compatible composition has a relatively high development and application value in treatment of the chronic obstructive pulmonary disease.

This application relates to the field of medicinal chemistry, specifically to a derivative of ligustilide-7-aminocarbamate-4'-substituted aminopropyl ether, its preparation method, and its application. Addressing the shortcomings of ligustilide in AD treatment, this application utilizes previous studies to demonstrate strong eeAChE and huACh inhibitory activity, strong inhibition of self-induction, and Cu... 2+ Induced Aβ 1‑42 Aggregation activity, significantly reduced Aβ 25‑35 The lead compound, scutellarin aglycone-4′-L-amino acid carbamate, which induces tau hyperphosphorylation and significantly improves learning and memory impairment in scopolamine-induced AD model mice, is used to introduce histamine H at the 7-position of its structure. 3 By using the key structural fragment (3-methylpiperidinyl) or cycloheptane group of the receptor antagonist, a cholinesterase inhibitor and histamine H2 receptor antagonist can be obtained. 3 Multi-targeted ligand derivatives with better anti-AD properties through receptor antagonistic synergistic mechanism.

The present invention belongs to the field of chemical medicine, and particularly relates to a combined drug of astragaloside IV, chlorogenic acid and scutellarin for treating chronic cerebral ischemia. The present invention provides the use of the combined use of astragaloside IV, chlorogenic acid and scutellarin in the preparation of a drug for preventing and / or treating chronic cerebral ischemia. In addition, calycosin can also be used as an additional component to be combined with the above three components to prepare a drug for preventing and / or treating chronic cerebral ischemia. The drug of the present invention can have synergistic effects, is used for treating chronic cerebral ischemia, and produces good therapeutic effects, providing a new option for the clinical treatment of chronic cerebral ischemia and having good application prospects.

This invention discloses the preparation method and uses of scutellarin 7-phosphate derivatives; belonging to the field of natural medicines and medicinal chemistry. The scutellarin 7-phosphate derivatives and their pharmaceutically acceptable salt structures described in this invention are shown in the following general formula I: By introducing a phosphate group at the 7-position, the scutellarin 7-phosphate derivatives are used in the preparation of drugs for cerebrovascular diseases. They exhibit excellent neuroprotective effects. The scutellarin phosphate derivatives of this invention have good protective activity against H2O2-induced oxidative damage to human neuroblastoma SH-SY5Y cells. Furthermore, the neuroprotective effects of some compounds are significantly stronger than those of the lead compound scutellarin.

The application discloses a plant growth regulating composition containing scutellarein and seminole, and belongs to the technical field of agricultural plant growth regulators. The mass ratio of scutellarein and seminole in the effective component of the plant growth regulating composition provided by the application is 1:30-13:1. It is proved that scutellarein and seminole have a synergistic effect when used for promoting crop growth and improving crop yield within the range of the ratio, and are particularly beneficial to improving the quality of crop fruits.